evipedia.ai
← Back

L-Ergothioneine for Health & Longevity

Evidence Review created on 10/23/2026 using AI4L / Opus 5.5

Also known as: Ergothioneine, EGT, ET, ERGO, Thioneine, Thiasine, 2-Mercaptohistidine Trimethylbetaine, ErgoActive, Ergoneine

Motivation

L-Ergothioneine (also called ergothioneine) is a sulfur-containing amino acid made only by certain fungi and soil bacteria. People cannot produce it and obtain it from food, mainly mushrooms. The body nevertheless absorbs it through a dedicated carrier and holds on to it for weeks, which has led researchers to ask whether it serves as a protective nutrient that matters for long-term health.

Interest grew when a prominent nutrition scientist proposed calling it a “longevity vitamin,” and when researchers began measuring how blood levels change with age. Large population studies have examined how blood levels relate to survival, while small clinical trials have tested supplements on memory and sleep in older adults. Purified versions, made by chemical synthesis or fermentation, are now sold as supplements in Europe, North America and Asia.

This review examines what the human, animal and laboratory evidence shows about ergothioneine supplements as a health and longevity strategy for proactive adults. It weighs the expected benefits against the risks, outlines the doses that have been studied, and examines how much of the evidence comes from independent versus commercial sources.

Benefits - Risks - Protocol - Conclusion

The following items give a high-level overview of ergothioneine, its biology and the case for and against it as a longevity nutrient.

Three priority expert sources qualified. Peter Attia’s and Andrew Huberman’s sites returned no results; Lifespan.io mentions it only in conference notices and news content.

Grokipedia

Ergothioneine

An encyclopedia-style overview of the chemistry, biosynthesis, dietary sources and transporter-mediated retention of ergothioneine, useful as background before the clinical literature.

Examine

No Examine article on ergothioneine exists. Examine.com covers it only within study summaries of mushroom trials.

ConsumerLab

Does ergothioneine help prevent age-related problems such as impaired cognition, Alzheimer’s disease, Parkinson’s disease or cataract, and is it safe?

A members-only answer covering studies on cognition, Parkinson’s disease, cataract and kidney disease, plus supplement safety, cost and dietary sources; ConsumerLab has not published product testing of ergothioneine.

Systematic Reviews

The following systematic reviews and meta-analyses address ergothioneine or its main dietary source.

No systematic review or meta-analysis addresses the risks or adverse effects of ergothioneine; the risk side is unrepresented.

Mechanism of Action

Ergothioneine enters cells almost exclusively through OCTN1, the protein made by the SLC22A4 gene (a transporter that pumps ergothioneine into cells), which was identified as its dedicated carrier in 2005 (Gründemann et al., 2005). Cells lacking the transporter barely take it up, so tissue levels track transporter expression: red blood cells and their bone-marrow precursors, liver, kidney, eye and brain accumulate the most.

  • Antioxidant and cytoprotective view: ergothioneine scavenges reactive oxygen and nitrogen species and binds metals in vitro, and it can enter mitochondria (Fong et al., 2024). One hypothesis holds that injured tissues raise transporter levels to concentrate it where damage occurs (Halliwell et al., 2018).
  • Competing view: the field’s leading group concludes that evidence for antioxidant action as its main function inside the body is weak (Halliwell et al., 2023).
  • Signaling view: in animals it activates MPST (3-mercaptopyruvate sulfurtransferase, a mitochondrial enzyme producing sulfur signaling molecules) (Sprenger et al., 2025) and serves as a substrate for CSE (cystathionine gamma-lyase, an enzyme producing hydrogen sulfide), raising NAD+ (nicotinamide adenine dinucleotide, a cellular energy cofactor) (Petrovic et al., 2025).

Pharmacology: oral doses are avidly absorbed and retained, with under 4% excreted in urine; whole-blood levels keep rising for weeks after dosing (Cheah et al., 2017). No formal elimination half-life has been established; retention spans weeks. Metabolism is minimal, producing hercynine and S-methyl-ergothioneine; no cytochrome P450 (liver drug-metabolizing enzyme) pathway has been reported.

Historical Context & Evolution

Ergothioneine was first isolated in 1909 from ergot, a grain fungus, and was soon found in human blood. For most of the twentieth century it was treated as a dietary curiosity with no intended medical use; its presence in red blood cells, semen and the eye had no clear explanation, and it later appeared among the popular botanical ingredients of cosmetic skin creams (Cronin & Draelos, 2010).

Three developments moved it toward health optimization:

  • Transporter discovery (2005): the identification of a carrier highly specific for ergothioneine suggested the body actively seeks and retains it, implying a physiological role (Gründemann et al., 2005).
  • Human depletion data (2016 onward): blood levels were found to decline after age 60 and to be lower in people with mild cognitive impairment (memory decline short of dementia) (Cheah et al., 2016), Parkinson’s disease (Hatano et al., 2016) and frailty (Kameda et al., 2020).
  • The “longevity vitamin” proposal (2018): Bruce Ames argued that modest shortfalls of such nutrients could quietly accelerate age-related disease (Ames, 2018).

Regulatory clearances then made purified ergothioneine widely available: European Union (EU) authorization for supplements in 2017 (Commission Implementing Decision (EU) 2017/1281) and a U.S. food-ingredient notice closed in 2018 (GRN No. 734). Opinion has since shifted from “antioxidant” toward “signaling molecule,” as animal work identified enzyme targets, while its leading researchers now question the antioxidant explanation. Whether low blood levels cause disease or merely mark poor diet or illness remains open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human clinical-outcome data are small randomized trials from single research groups and observational blood-level associations, with no clinical endpoint replicated by independent groups.

Medium 🟩 🟩

Subjective sleep quality ⚠️ Conflicted

A randomized placebo-controlled trial co-authored by Suntory employees with Kanazawa University reported better subjective sleep with 8 mg/day for 16 weeks (Okumura et al., 2025). In a separate trial funded by supplier Blue California, 25 mg/day improved only “getting to sleep,” significant among protocol completers but not the full randomized sample (Zajac et al., 2025); its abstract omits this distinction. Net reading: a modest subjective benefit, shown consistently only by one company-linked group.

Magnitude: Subjective sleep quality was significantly better than placebo with 8 mg/day for 16 weeks (p < 0.05, the probability of such a result by chance alone); the reports give no between-group effect size, so the literature reports no outcome figure.

Low 🟩

Cognitive performance in older adults ⚠️ Conflicted

A one-year trial in 19 adults with mild cognitive impairment reported better learning than placebo (Yau et al., 2024). A shorter 147-person trial in unimpaired adults found no composite-memory difference (Zajac et al., 2025), possibly reflecting population and duration differences. Net reading: the larger null trial outweighs the positive one.

Magnitude: Composite memory changed by +0.22 points (95% confidence interval, CI, the range likely to contain the true value: −3.70 to 4.14) with 25 mg/day versus +3.25 (95% CI −0.85 to 7.35) with placebo at 16 weeks, with no significant treatment effect; not compared between groups as a single figure.

Lower cardiovascular disease and mortality risk

In 3,236 Swedish adults followed for a median 21 years, higher plasma ergothioneine predicted fewer coronary events and deaths (Smith et al., 2020). Evidence is indirect: blood levels reflect diet, not supplementation, and no trial has tested supplements. Oral ergothioneine extended lifespan in male mice (Katsube et al., 2024).

Magnitude: Per one standard deviation (a measure of spread) higher plasma ergothioneine, the fully adjusted hazard ratio (HR, the relative rate of an event over time) was 0.85 for coronary disease, 0.79 for cardiovascular death and 0.86 for all-cause death (observational).

Skin hydration and wrinkle appearance

In 80 healthy Japanese women, ergothioneine-rich mushroom tablets (25 mg/day) for 12 weeks improved temple skin moisture and wrinkle scores versus placebo (Hanayama et al., 2024). Evidence is indirect (whole mushroom, not purified compound); the sponsor, Hokuto Corporation, sells mushrooms.

Magnitude: Temple skin moisture was significantly higher than placebo at 8 weeks and wrinkle and texture scores significantly better at 12 weeks; the report gives no between-group effect size, so the literature reports no outcome figure.

Ovarian reserve markers in women aged 35–45

An open-label study of 40 women reported higher anti-Müllerian hormone (AMH, a blood marker of remaining egg supply) after 120 mg/day for three cycles (Liu et al., 2026). It had no control group, used four times the EU supplement maximum, and was run by manufacturer Gene III.

Magnitude: Mean AMH rose by 0.65 ng/mL (95% CI 0.14 to 1.17) from baseline; no control group.

Speculative 🟨

Exercise capacity and mitochondrial function

By activating MPST, ergothioneine boosted mitochondrial respiration and training performance in mice (Sprenger et al., 2025); via CSE, it improved endurance in aged rats (Petrovic et al., 2025, erratum published). Basis is animal-only.

Reduced oxidative damage and inflammation

Pure ergothioneine for one week produced mostly non-significant downward trends in oxidative-damage markers and C-reactive protein (a blood marker of inflammation) (Cheah et al., 2017). These are unvalidated biomarkers.

Telomere maintenance

Telomeres (protective chromosome end caps) lengthened within the 10 mg/day group, mainly in women, without a difference from placebo (Zajac et al., 2025). Basis is an exploratory unvalidated biomarker.

Benefit-Modifying Factors

  • Genetic polymorphisms: the common SLC22A4 L503F variant alters the transporter’s substrate handling and occurs in about 42% of European-American alleles (Urban et al., 2007); carriers showed higher tissue ergothioneine (Taubert et al., 2009). Effects on benefit are untested.
  • Baseline blood levels: in the skin trial, women with low baseline plasma ergothioneine (below 3.3 μM) showed clearer moisture gains (Hanayama et al., 2024); the memory-trial authors (Zajac et al., 2025) likewise suggest benefit may concentrate in people with low baseline levels.
  • Sex: the telomere change appeared mainly in women and liver-enzyme improvements mainly in men (Zajac et al., 2025); the mouse lifespan gain was shown only in males.
  • Pre-existing conditions: chronic kidney disease impaired intestinal uptake in mice and lowers blood ergothioneine in patients (Shinozaki et al., 2017); low levels track with cognitive impairment, so these groups may have more to restore.
  • Age: whole-blood levels decline after 60 (Cheah et al., 2016), and lower plasma levels predicted faster cognitive decline in older adults without dementia (Wu et al., 2022).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no randomized trial has documented a clinical adverse event attributable to ergothioneine, and no regulator lists one.

Medium 🟥 🟥

No risk reaches Medium: human safety data consist of laboratory values from single trials of up to one year, none showing a clinical adverse event attributable to ergothioneine.

Low 🟥

Small blood-count shifts ⚠️ Conflicted

In the 147-person trial, hemoglobin fell slightly with 10 mg/day while placebo was unchanged, all values staying within normal ranges (Zajac et al., 2025). A one-year trial found no change in blood counts (Yau et al., 2024). Net reading: no clinically meaningful signal.

Magnitude: Hemoglobin changed by −1.91 (95% CI −3.35 to −0.47, trial units) with 10 mg/day versus no change with placebo, not compared between groups as a figure; the source reports no adverse-event rates, and no product-related adverse events occurred.

Speculative 🟨

Rise in trimethylamine N-oxide ⚠️ Conflicted

Gut bacteria can convert ergothioneine into the precursor of trimethylamine N-oxide (TMAO, a heart-disease-linked metabolite). Trials found no TMAO rise (Cheah et al., 2026; Zajac et al., 2025). Net reading: this biomarker concern is unsupported.

Possible support of tumor-cell growth

The ergothioneine transporter is implicated in cancer progression, and blocking it slowed cancer-cell growth in vitro (Xu et al., 2026). Whether supplements feed tumors is untested; basis is mechanistic only.

Unknown effects in pregnancy

Rat studies found no reproductive toxicity (Forster et al., 2015; co-authored by manufacturer Tetrahedron). No human pregnancy data exist; basis is animal-only.

Risk-Modifying Factors

  • Genetic polymorphisms: rare loss-of-function SLC22A4 variants abolish transport (Urban et al., 2007), limiting uptake; the common L503F variant changes how the transporter handles drugs such as gabapentin (Urban et al., 2008).
  • Baseline biomarkers: people with low hemoglobin or reduced kidney function have the least margin for the small laboratory shifts seen in trials; kidney function also governs ergothioneine retention.
  • Sex: no sex difference in adverse effects has been reported; pregnant and lactating women fall under the EU regulatory exclusion (Commission Implementing Decision (EU) 2017/1281).
  • Pre-existing conditions: active cancer raises the theoretical tumor-support concern; people on dialysis have low levels and altered clearance, and supplementation is still under study.
  • Age: adults aged 60 and over tolerated 25 mg three times weekly for one year (Yau et al., 2024); taking several medications raises interaction exposure. EU limits for children over 3 are lower (Commission Implementing Decision (EU) 2017/1281).

Key Interactions & Contraindications

  • Gabapentin (anticonvulsant, nerve-pain drug): Monitor. A high-shiitake diet that raised plasma ergothioneine increased gabapentin kidney clearance (91.1 vs 76.9 mL/min) without changing total exposure (Toh et al., 2014); clinical consequence likely minimal.
  • Biguanides (metformin, buformin; blood-sugar-lowering diabetes drugs): Monitor (theoretical). These share the ergothioneine transporter, especially its L503F form (Futatsugi et al., 2016); competition could alter metformin absorption and blood-sugar control. No human study.
  • Calcium-channel blockers (verapamil; blood-pressure and heart-rhythm drugs): Monitor (theoretical). Verapamil was the most potent inhibitor of the ergothioneine transporter in cells (Grigat et al., 2007), possibly reducing ergothioneine uptake and benefit.
  • Nucleoside-analogue chemotherapy (cytarabine, gemcitabine; cancer drugs that mimic DNA building blocks): Caution (theoretical). The same transporter carries these drugs into leukemia cells (Drenberg et al., 2017); competition might reduce tumor drug uptake; timing is typically coordinated with the oncologist.
  • Platinum chemotherapy (oxaliplatin): Caution (theoretical). The transporter carries oxaliplatin into nerve cells (Jong et al., 2011); competition could lessen nerve damage, with untested effects on human tumor response; it protected cultured neurons and did not lower antitumor effect in mice (Yamada et al., 2025).
  • Over-the-counter medications (acetaminophen, ibuprofen, antihistamines): No interaction reported in any label, regulator document or human study; none known.
  • Ergothioneine-rich extracts and fortified foods (mushroom extracts, functional drinks): Monitor. They add to total intake; the EU maximum for food supplements is 30 mg/day for adults (Commission Implementing Decision (EU) 2017/1281); combining supplement products can exceed it.
  • Sleep-supporting supplements (melatonin, glycine, magnesium): Monitor (theoretical). Additive effects on sleep onset are possible; no study has tested the combination, and no harm is known.
  • Other antioxidants (N-acetylcysteine, vitamin C, vitamin E): Monitor (theoretical). Overlapping antioxidant actions could be additive or redundant; no human interaction data exist.
  • Hemodialysis: Monitor (theoretical). Dialysis lowers blood ergothioneine, and a randomized repletion trial is under way (NCT06487546); dosing in kidney failure is not established.

Populations who should avoid L-Ergothioneine:

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Staying within the regulatory ceiling: total supplemental intake at or below 30 mg/day for adults (Commission Implementing Decision (EU) 2017/1281), a use the European Food Safety Authority (EFSA) judged safe, limits exposure beyond tested doses.
  • Avoidance during pregnancy and lactation: stopping supplements when pregnancy is planned or confirmed avoids unknown fetal risk; no human pregnancy safety data exist and EU authorization excludes these groups (Commission Implementing Decision (EU) 2017/1281).
  • Baseline and follow-up blood count: hemoglobin measured before starting and after 3–4 months detects the small shifts reported with 10 mg/day (Zajac et al., 2025); values below the laboratory reference range warrant medical review.
  • Kidney check: baseline creatinine and estimated glomerular filtration rate (eGFR, a calculated measure of kidney filtering capacity) identify impaired kidney function, which alters ergothioneine retention.
  • Disclosure during cancer treatment: informing the oncologist before or during chemotherapy addresses theoretical transporter competition and possible tumor-support effects.
  • Gabapentin users: noting dizziness or reduced symptom control after starting helps detect consequences of the small clearance change seen with high-ergothioneine diets (Toh et al., 2014).
  • Pure, specified products: products meeting the EU purity specification (at least 99.5%; Commission Implementing Decision (EU) 2017/1281) reduce the risk of contaminants and dosing errors.

Therapeutic Protocol

Timing, cycling and other parameters below without a citation reflect common practice.

  • Standard dose: 5–25 mg/day in most trials (Cheah et al., 2017; Zajac et al., 2025); others used 80 mg/day (NCT05190432) or 120 mg/day (Liu et al., 2026); EU supplement maximum 30 mg/day for adults (Commission Implementing Decision (EU) 2017/1281).
  • Sleep-focused dosing: 8 mg/day for 16 weeks, chosen by pharmacokinetic modeling to reach an effective plasma level (Okumura et al., 2025).
  • Intermittent dosing: 25 mg three times weekly for one year in older adults with mild cognitive impairment (Yau et al., 2024), exploiting long tissue retention.
  • Food-first alternative: regular mushroom intake, especially high-content species such as porcini and oyster mushrooms, which range widely in ergothioneine content (Kalaras et al., 2017); supplements give a defined dose.
  • Popularizers: Bruce Ames framed it as a “longevity vitamin” (Ames, 2018); Barry Halliwell and Irwin Cheah’s Singapore group ran the first human dosing studies (Cheah et al., 2017); Blue California and Suntory sponsor most current trials.
  • Time of day: no study has compared timing; given weeks-long retention, timing matters little, and common practice is once daily with a meal.
  • Half-life: retention lasts weeks to months, with under 4% excreted in urine (Cheah et al., 2017), so levels build gradually over 4–16 weeks.
  • Single versus split dose: a single daily dose suffices because blood levels are stable; splitting offers no known advantage.
  • Genetic polymorphisms: SLC22A4 variants (L503F, rare loss-of-function alleles) may alter uptake; no genotype-guided dosing exists.
  • Sex: no sex-specific dosing exists; exploratory sex differences in liver enzymes and telomere length were reported at 10–25 mg/day (Zajac et al., 2025).
  • Age: older adults have lower baseline levels and were the main trial population (aged 55 and over), receiving 10–25 mg/day (Zajac et al., 2025; Yau et al., 2024).
  • Baseline biomarker levels: plasma ergothioneine testing is research-only; those with low intake of mushrooms may respond more, as suggested by low-baseline subgroup results (Hanayama et al., 2024).
  • Pre-existing conditions: kidney failure lowers levels and alters handling; dosing in dialysis is under trial and not established.

Discontinuation & Cycling

  • Duration: framed as a long-term nutritional strategy rather than a short course; the longest human trial lasted one year (Yau et al., 2024).
  • Withdrawal effects: none reported; ergothioneine is not habit-forming and stopping produces no rebound effects in any study.
  • Tapering: not needed; because tissues retain ergothioneine for weeks, levels decline slowly after stopping without any taper.
  • Cycling: no evidence supports cycling to maintain efficacy; the transporter is not known to down-regulate with continued intake.

Sourcing and Quality

  • Forms: purified L-Ergothioneine is made by chemical synthesis (Ergoneine, Tetrahedron) or by microbial fermentation (ErgoActive, Blue California); mushroom powders and extracts contain variable amounts.
  • Purity: the EU specification requires at least 99.5% purity by high-performance liquid chromatography, with limits on solvents and heavy metals (Commission Implementing Decision (EU) 2017/1281).
  • Third-party testing: certificates of analysis or independent seals (United States Pharmacopeia, NSF International) provide verification; ConsumerLab has not tested ergothioneine products, so most verification relies on manufacturer documentation.
  • Regulatory filings: ingredients with a U.S. Food and Drug Administration (FDA) “no questions” letter on generally recognized as safe (GRAS) status offer documented specifications (GRN No. 734).
  • Brands: Life Extension sells 5 mg and 25 mg capsules; many brands use branded ErgoActive or Ergoneine ingredients, which carry documented specifications, unlike unspecified “mushroom blends.”
  • Combination products: ergothioneine is often bundled with other compounds, which obscures the dose; single-ingredient products allow accurate intake tracking.

Practical Considerations

  • Time to effect: plasma levels rise within days, but whole-blood levels keep climbing for weeks; sleep effects appeared after 4–16 weeks and skin effects after 8–12 weeks in trials.
  • Common pitfalls: assuming rising blood levels equal proven benefit; stacking multiple ergothioneine sources beyond 30 mg/day; relying on mushroom blends of unknown content; expecting acute effects.
  • Regulatory status: authorized in the EU as a novel food for supplements (Commission Implementing Decision (EU) 2017/1281); GRAS for specified foods in the U.S. (GRN No. 734); not an approved drug anywhere.
  • Cost and access: widely available and not exceptionally expensive; neither supplements nor mushrooms are reimbursed by insurers, so no payer incentive favors one route.

Interaction with Foundational Habits

  • Sleep: potentiating (possible). Small trials suggest better subjective sleep and sleep onset after weeks of use (Okumura et al., 2025); in rats it prevented stress-induced sleep disruption (Matsuda et al., 2020). No evidence of sleep disruption.
  • Nutrition: direct. Mushrooms are the main dietary source and contents vary widely by species (Kalaras et al., 2017); including them supplies ergothioneine with other nutrients. No nutrient depletion is known; it can be taken with or without food.
  • Exercise: potentiating (animal only). Ergothioneine accumulates in muscle mitochondria with training and enhanced training performance in mice through MPST (Sprenger et al., 2025); no evidence it blunts training adaptation in humans.
  • Stress management: indirect. Lower serum ergothioneine was associated with higher psychological distress in older Australians (Sotgia et al., 2024); in rats it buffered social-stress effects on sleep (Matsuda et al., 2020). No effect on cortisol has been shown.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes the safety reference points against which later values are compared: a complete blood count with hemoglobin, serum creatinine with eGFR, and liver enzymes. People who can access a research laboratory may add a plasma or whole-blood ergothioneine measurement to document their starting level and confirm uptake later. Baseline ratings of sleep quality and memory complaints using the same questionnaire each time make later changes interpretable.

Ongoing monitoring repeats the blood count, kidney and liver tests at about 3–4 months, then every 6–12 months while supplementation continues. Sleep and memory ratings are repeated at 4 weeks, 16 weeks and then every 6 months, matching the time frames in which trials detected changes. Success is defined as stable safety labs plus a sustained subjective improvement; a rising ergothioneine level alone does not establish benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Plasma or whole-blood ergothioneine No established target; track change from the individual’s own baseline Expected to change; confirms uptake Research assays only; trial baselines differ by assay (about 1.1 μM plasma in Zajac et al., 2025, 3.4 μM in Hanayama et al., 2024); whole-blood levels lag plasma by weeks
Hemoglobin Women 12.0–15.5 g/dL; men 13.5–17.5 g/dL (standard reference range) Safety check; a fall below range changes use Small decreases reported with 10 mg/day (Zajac et al., 2025); no fasting needed; part of a complete blood count (CBC)
Serum creatinine and eGFR Creatinine 0.6–1.3 mg/dL (standard reference range); for eGFR, no established target, track change from own baseline Safety check; reduced function changes dosing Kidney function governs ergothioneine retention; heavy exercise in the 24 h before testing can raise creatinine
ALT and AST ALT 7–56 U/L; AST 8–48 U/L (standard reference range) Safety check; also possibly changed (exploratory decrease in men) ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes; morning sample; alcohol in the 24–48 h before testing can raise values

Qualitative markers:

  • Sleep onset and overall sleep quality (same questionnaire or sleep diary each time)
  • Subjective memory, especially everyday prospective memory (remembering to do planned tasks)
  • Daytime energy and mental clarity
  • Skin hydration and texture (self-assessment or photographs under consistent lighting)

Emerging Research

  • Mushroom powder for cognitive decline: a 600-person, 24-month randomized trial of an ergothioneine-rich mushroom powder in at-risk adults aged 45–80, primary endpoint Mini-Mental State Examination (NCT07775833); a positive result would raise the cognition grade, a null result would weaken it.
  • Repletion in kidney failure: a 28-person randomized placebo-controlled trial of daily ergothioneine for 12 weeks in dialysis patients, primary endpoint red-cell ergothioneine (NCT06487546); positive results would support dosing in kidney failure, null results would question oral repletion.
  • Healthy aging biomarkers: a 50-person, 12-week placebo-controlled trial of a branded ergothioneine in adults aged 40–65, primary endpoint oxidative DNA damage marker 8-OHdG (8-hydroxy-2’-deoxyguanosine) (NCT07750002); a positive result would support antioxidant effects, a null result would weaken them.
  • Immune function trial (TaxEr): a 90-person randomized trial of ergothioneine or taxifolin on immune markers (NCT05190432); registered completion July 2026 has passed, status listed as active, not recruiting, no results posted. Positive results would support immune benefit; null results would remove it.
  • Personalized geromedicine (PROMETHEUS): a 20-person feasibility study adding ergothioneine for poor cognitive response (NCT07451496; protocol in Kuerec et al., 2026); registered completion June 2026 has passed, status still listed as recruiting, no results posted. Positive feasibility data would enable a randomized trial; null data would not change grades.
  • Exercise and mitochondria: animal targets MPST and CSE (Sprenger et al., 2025; Petrovic et al., 2025) await human exercise trials, which could strengthen or refute muscle claims.
  • Cancer biology: structural work links the ergothioneine transporter to cancer-cell proliferation (Xu et al., 2026); further study could weaken the case for use in people with cancer.
  • Causality of low levels: the hypothesis that deficiency drives neurodegeneration (Halliwell & Cheah, 2024) needs long trials; genotype-stratified designs are proposed (Zhao & Qi, 2026).

Conclusion

L-Ergothioneine is a mushroom-derived nutrient that the body absorbs through its own dedicated carrier and keeps for weeks, and blood levels tend to fall with age. That biology, together with population studies linking higher blood levels to better heart health, longer survival and slower mental decline, explains its appeal to people investing in long-term health.

The evidence that taking it as a supplement improves health is far thinner. The most consistent human signal is a modest improvement in how well people feel they sleep, seen mainly in small company-funded trials. Effects on memory are mixed, with the largest trial finding no clear benefit. The links to heart disease and survival come from blood levels that partly reflect a healthy diet, not from supplement trials. Claims of longer life and better exercise capacity rest on animal studies.

Safety appears favorable at the studied amounts: trials of up to a year report no harms attributable to it, and European food-safety experts judged it safe within set limits. Gaps remain for pregnancy, people with cancer, people on dialysis and higher amounts.

Much of the human research is funded or run by companies that make or sell ergothioneine, which limits confidence in the positive findings. For health-focused adults, the current picture is of a low-risk nutrient whose benefits remain plausible but unproven.

Top - Benefits - Risks - Protocol